This work was supported by a grant from the EB-NCRC (grant no. R15-2003-012-01001-0) and (grant no. R01-2007-000-20299-0) supported by the KSEF/MOST of Korea. BODIPY=4,4-difluoro-4-bora-3a,4a-diaza-s-indacene.
A Selective Fluoroionophore Based on BODIPY-functionalized Magnetic Silica Nanoparticles: Removal of Pb2+ from Human Blood†
Article first published online: 7 JAN 2009
Copyright © 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 48, Issue 7, pages 1239–1243, February 2, 2009
How to Cite
Lee, H., Bae, D., Park, J., Song, H., Han, W. and Jung, J. (2009), A Selective Fluoroionophore Based on BODIPY-functionalized Magnetic Silica Nanoparticles: Removal of Pb2+ from Human Blood. Angew. Chem. Int. Ed., 48: 1239–1243. doi: 10.1002/anie.200804714
- Issue published online: 28 JAN 2009
- Article first published online: 7 JAN 2009
- Manuscript Revised: 10 DEC 2008
- Manuscript Received: 26 SEP 2008
- EB-NCRC. Grant Numbers: R15-2003-012-01001-0, R01-2007-000-20299-0
Get the lead out: The title fluorescence receptor exhibits a high affinity and selectivity for Pb2+ over competing metal ions in water (see picture) with an overall emission change of approximately 8-fold at the emission maximum for Pb2+. The fluorescence receptor can remove 96 % of 100 ppb Pb2+ from human blood, and can be useful and effective for the selective and rapid removal of Pb2+ in vivo.